Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients.

ABSTRACT:

Background

Coronavirus disease 2019 (COVID-19) pandemic stimulates research works to find a solution to this crisis from starting 2020 year up to now. With ending of the 2021-year, various advances in pharmacotherapy against COVID-19 have emerged. Regarding antiviral therapy, casirivimab and imdevimab antibody combination is a type of new immunotherapy against COVID-19. Standard antiviral therapy against COVID-19 includes Remdesivir and Favipiravir.

Aim

To evaluate the efficacy of antibodies cocktail (casirivimab and imdevimab) compared to standard antiviral therapy in reducing the need for invasive mechanical ventilation (IMV).

Methods

265 COVID-19 polymerase chain reaction confirmed patients with indication for antiviral therapy were included in this study and were

SUBMITTER: Hegazy SK 

PROVIDER: S-EPMC10507553 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature